K. Agarwal Et Al. , "Long-Term Clinical Outcomes in HCV Genotype 1-Infected Patients Receiving Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir +/- Ribavirin: First interim Safety and Efficacy Results from TOPAZ-I," 67th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) , vol.64, Massachusetts, United States Of America, 2016
Agarwal, K. Et Al. 2016. Long-Term Clinical Outcomes in HCV Genotype 1-Infected Patients Receiving Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir +/- Ribavirin: First interim Safety and Efficacy Results from TOPAZ-I. 67th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) , (Massachusetts, United States Of America).
Agarwal, K., Dumas, E. O., Gaeta, G. B., Lee, S., Streinu-Cercel, A., Schott, E., ... Andrade, R. J.(2016). Long-Term Clinical Outcomes in HCV Genotype 1-Infected Patients Receiving Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir +/- Ribavirin: First interim Safety and Efficacy Results from TOPAZ-I . 67th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD), Massachusetts, United States Of America
Agarwal, Kosh Et Al. "Long-Term Clinical Outcomes in HCV Genotype 1-Infected Patients Receiving Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir +/- Ribavirin: First interim Safety and Efficacy Results from TOPAZ-I," 67th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD), Massachusetts, United States Of America, 2016
Agarwal, Kosh Et Al. "Long-Term Clinical Outcomes in HCV Genotype 1-Infected Patients Receiving Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir +/- Ribavirin: First interim Safety and Efficacy Results from TOPAZ-I." 67th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) , Massachusetts, United States Of America, 2016
Agarwal, K. Et Al. (2016) . "Long-Term Clinical Outcomes in HCV Genotype 1-Infected Patients Receiving Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir +/- Ribavirin: First interim Safety and Efficacy Results from TOPAZ-I." 67th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) , Massachusetts, United States Of America.
@conferencepaper{conferencepaper, author={Kosh Agarwal Et Al. }, title={Long-Term Clinical Outcomes in HCV Genotype 1-Infected Patients Receiving Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir +/- Ribavirin: First interim Safety and Efficacy Results from TOPAZ-I}, congress name={67th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD)}, city={Massachusetts}, country={United States Of America}, year={2016}}